Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

Objectives Management with vitamin K antagonists (VKAs) has been an effective and cost-
effective strategy for stroke prevention in atrial fibrillation (AF) but is associated with …

Introduction: In the Randomized Evaluation of Long-term Anticoagulant Therapy (RE-LY)
trial, dabigatran 150 mg was shown to be superior to warfarin for the prevention of stroke or …

Objective The prevalence of atrial fibrillation (AF) and the risk of stroke and bleeding vary
according to age. To estimate effects of dabigatran, compared with warfarin, on stroke …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …

In the RE-LY clinical trial, dabigatran presented a better effectiveness/safety profile when
compared to warfarin. However, clinical trials are not very representative of the real-world …